drugset

drugset / Trial / NCT00443391

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

NCT00443391 ↗

Phase 2 Completed 141 enrolled AbbVie

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.

Timeline

Start: 2007-02
Primary completion: 2008-10
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pozanicline	Small molecule	80 mg	—

Indications